MindWalk Holdings Corp. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market

Reuters

09/22

<a href="https://laohu8.com/S/HYFT">MindWalk Holdings Corp</a>. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market

MindWalk Holdings Corp., a Bio-Native AI company, has announced significant advancements in its AI-designed GLP-1 therapeutics program. The company is pioneering a first-in-class dual-pathway regimen that involves the co-administration of its proprietary companion therapeutic with GLP-1 receptor agonists. This approach targets a newly discovered connection between GLP-1 biology and a separate pathway linked to healthy aging and systemic resilience. To date, no approved or marketed drugs utilize this regimen. MindWalk's proprietary companion therapeutic is an exclusive asset, not a repurposed or co-branded product. The company plans to provide updates on lead selection, preclinical combination design parameters, and potential development paths in the coming quarters. Results from the ongoing efforts have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922510586) on September 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2569786723"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569786723\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569786723?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569786723","market":"fut","top_or_hot":-1,"title":"MindWalk Holdings Corp. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HYFT\">MindWalk Holdings Corp</a>. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MindWalk Holdings Corp., a Bio-Native AI company, has announced significant advancements in its AI-designed GLP-1 therapeutics program. The company is pioneering a first-in-class dual-pathway regimen that involves the co-administration of its proprietary companion therapeutic with GLP-1 receptor agonists. This approach targets a newly discovered connection between GLP-1 biology and a separate pathway linked to healthy aging and systemic resilience. To date, no approved or marketed drugs utilize this regimen. MindWalk's proprietary companion therapeutic is an exclusive asset, not a repurposed or co-branded product. The company plans to provide updates on lead selection, preclinical combination design parameters, and potential development paths in the coming quarters. Results from the ongoing efforts have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922510586) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindWalk Holdings Corp. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindWalk Holdings Corp. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-22 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HYFT\">MindWalk Holdings Corp</a>. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MindWalk Holdings Corp., a Bio-Native AI company, has announced significant advancements in its AI-designed GLP-1 therapeutics program. The company is pioneering a first-in-class dual-pathway regimen that involves the co-administration of its proprietary companion therapeutic with GLP-1 receptor agonists. This approach targets a newly discovered connection between GLP-1 biology and a separate pathway linked to healthy aging and systemic resilience. To date, no approved or marketed drugs utilize this regimen. MindWalk's proprietary companion therapeutic is an exclusive asset, not a repurposed or co-branded product. The company plans to provide updates on lead selection, preclinical combination design parameters, and potential development paths in the coming quarters. Results from the ongoing efforts have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922510586) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HYFT","symbol_name":"MindWalk Holdings Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL4CdbJ3:1","article_id":"2569786723","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569786723","pubTimestamp":1758538940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MindWalk Holdings Corp., a Bio-Native AI company, has announced significant advancements in its AI-designed GLP-1 therapeutics program. The company is pioneering a first-in-class dual-pathway regimen that involves the co-administration of its proprietary companion therapeutic with GLP-1 receptor agonists. This approach targets a newly discovered connection between GLP-1 biology and a separate pathway linked to healthy aging and systemic resilience. To date, no approved or marketed drugs utilize this regimen. MindWalk's proprietary companion therapeutic is an exclusive asset, not a repurposed or co-branded product. The company plans to provide updates on lead selection, preclinical combination design parameters, and potential development paths in the coming quarters. Results from the ongoing efforts have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inform","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HYFT":"MindWalk Holdings Corp","BK4121":"生命科学工具和服务"},"translate_title":"MindWalk Holdings Corp.推出人工智能驱动的抗衰老和长寿双途径GLP-1方案，瞄准60B美元市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HYFT":0.9},"content_text":"MindWalk Holdings Corp. Unveils AI-Driven Dual-Pathway GLP-1 Regimen for Aging and Longevity, Targeting $60B Market\n    \n\n        MindWalk Holdings Corp., a Bio-Native AI company, has announced significant advancements in its AI-designed GLP-1 therapeutics program. The company is pioneering a first-in-class dual-pathway regimen that involves the co-administration of its proprietary companion therapeutic with GLP-1 receptor agonists. This approach targets a newly discovered connection between GLP-1 biology and a separate pathway linked to healthy aging and systemic resilience. To date, no approved or marketed drugs utilize this regimen. MindWalk's proprietary companion therapeutic is an exclusive asset, not a repurposed or co-branded product. The company plans to provide updates on lead selection, preclinical combination design parameters, and potential development paths in the coming quarters. Results from the ongoing efforts have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922510586) on September 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}